Emerging Companies

The study provides first-of-its-kind data on the importance of university/industry research and development partnerships to the U.S. economy.

The health reform debate is heating up and, in at least one respect, slowing down a bit.

Tracy Krughoff speaks with Fernando Quesada, executive director of the Biotechnology Center of Excellence Corporation, who is organizing Mexico’s participation in the BIO International Convention.

We have used the biological processes of microorganisms for 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.

Today, the biotechnology industry is enjoying more success and influence than ever before. Our industry’s innovations continue to improve the lives of people worldwide, and the advancement of these innovations is supported by the work of BIO.

States and regions throughout the United States are investing to create a business climate that supports the specific needs of the biosciences sector.

Dr. Moira Gunn and David Ewing Duncan report from the BIO International Convention.

Letters, Testimony & Comments

April 30 2015
On behalf of the Biotechnology Industry Organization Before the United States House of Representatives Committee on Financial Services, Subcommittee on Capital Markets and Government Sponsored Enterprises --- Legislative Proposals to Enhance Capital Formation and Reduce Regulatory Burdens
April 29 2014
Chairperson Mikulski, Ranking Member Shelby, Members of the Committee, thank you for the opportunity to provide you with written testimony on the extremely important topic of driving innovation through federal investments.
November 6 2013
On behalf of the BIO and its 1,100 members, I am writing in strong support of your Start-up Jobs and Innovation Act. I want to thank you for introducing this important legislation, which will spur investment in small biotech companies and other innovative businesses.
July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.

Press Releases

August 11 2015
BIO Investor Forum to be held October 20-21 in San Francisco, California  
June 11 2015
BIO released a new report - Emerging Therapeutic Company Investment and Deal Trends – highlighting ten years (2005-2014) of biotechnology funding and deal making across five areas: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions. The report also offers a first-time look at the degree of collaboration across the industry’s clinical pipeline.
May 21 2015
By making this tax credit permanent, companies conducting their development programs will be able to estimate their tax liability and will not be burdened by the constant uncertainty regarding whether or not the R&D Tax Credit will be extended.
May 13 2015
By teaming up with Aon, we are able to offer our members state-of-the-art coverage enhancements specific for life sciences companies...
May 7 2015
Program will improve liquidity and enhance capital formation for emerging biotech companies